SCIENTIFIC JOURNAL of the Hungarian Society of Cardiology

Effectiveness of prolonged-release trimetazidine of the ONECAPS study population stratified by age. A multicenter, prospective, observational study

█ Opinion

DOI: 10.26430/CHUNGARICA.2020.50.3.206

Authors:
Tomcsányi János1, Jánosi István2, Szakács László2
1Betegápoló Irgalmasrend, Budai Irgalmasrendi Kórháza, Kardiológia, Budapest
2WEB2 Research Kft., Budapest

Summary

Effectiveness of prolonged-release trimetazidine of the ONECAPS study population stratified by age. A multicenter, prospective, observational study.
This study evaluated the effectiveness of prolonged-release trimetazidine 80 mg treated patient population in the ONECAPS study stratified by age. 1701 subjects with stable angina pectoris were divided into three groups: 1. <60 years (294), 2. 60–70 years (667), 3. >70 years (740). The findings of present study highlight, that prolonged-release trimetazidine, reduced significantly (p <0.0001) the number of weekly angina attacks regardless of age.
Once a day administered prolonged-release trimetazidine was beneficial not only because of its anti-ischemic effects, but due to increased adherence compared to trimetazidine MR and that was consistent across all age groups.

ISSUE: CARDIOLOGIA HUNGARICA | 2020 | VOLUME 50, ISSUE 3

click here to read the full article

click here to read the pdf